Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. journal of experimental medicine Kurnellas, M. P., Schartner, J. M., Fathman, C. G., Jagger, A., Steinman, L., Rothbard, J. B. 2014; 211 (9): 1847-1856

Abstract

Amyloid fibrils composed of peptides as short as six amino acids are effective therapeutics for experimental autoimmune encephalomyelitis (EAE). Immunosuppression arises from at least two pathways: (1) expression of type 1 IFN by pDCs, which were induced by neutrophil extracellular traps arising from the endocytosis of the fibrils; and (2) the reduced expression of IFN-?, TNF, and IL-6. The two independent pathways stimulated by the fibrils can act in concert to be immunosuppressive in Th1 indications, or in opposition, resulting in inflammation when Th17 T lymphocytes are predominant. The generation of type 1 IFN can be minimized by using polar, nonionizable, amyloidogenic peptides, which are effective in both Th1 and Th17 polarized EAE.

View details for DOI 10.1084/jem.20140107

View details for PubMedID 25073790

View details for PubMedCentralID PMC4144739